We would love to hear your thoughts about our site and services, please take our survey here.
Wishing each and everyone of you peace joy and happiness
May you have walls for the winds, a roof for the rain and tea beside the fire. Laughter to cheer you, those you love near you, and all your heart might desire. May joy and peace surround you, Contentment latch your door, And happiness be with you now, And bless you evermore
As 2023 draws to a close, we reflect on another successful year which saw some significant milestones for Scancell.
We were very pleased to announce positive data from the first stage of our Phase 2 SCOPE trial with the cancer vaccine, SCIB1, for advanced melanoma, demonstrating an objective response rate of 85%. The trial moved into its second phase and is on track to read-out in H1 2024. Based upon the first 13 patients, there is a greater than 90% probability that the second phase will also be successful.
We also continued to make good progress with Modi-1, the first vaccine based on our Moditope® platform, completing dose escalation and safety cohorts in the Phase 1/2 ModiFY trial demonstrating early signs of efficacy in several hard-to-treat cancers. We are expecting early clinical data for Modi-1 in 2024.
Scancell’s GlyMab® and AvidiMab® antibody platforms have also demonstrated significant potential for licensing opportunities, with discussions ongoing with several Pharmaceutical and Biotech companies.
Over the course of the year, we have further strengthened the management team and were delighted to appoint Dr @Jean-Michel Cosséry as Non-Executive Chairman of the Board and welcome our new Chief Financial Officer Sath Nirmalananthan and Head of Business Development Mandeep Sehmi to the Scancell family.
To close the year, we were pleased to announce a successful oversubscribed and upsized fundraise of [£11.9] million and would like to thank our new and existing investors for their support.
Finally, we would also like to thank the whole Scancell team for their continued efforts and hard work during 2023. Now, with a bolstered leadership team, a strong cash position to fund our current strategy and with further key data inflection points from both the SCOPE and ModiFY trial anticipated, 2024 looks to be another exciting year.
#Immunotherapy #Cancervaccines #cancervax #Immunooncology #HappyNewYear #2024
It may be time-consuming and costly to constantly update the vaccine according to the sequence of new variants, so a broad-spectrum vaccine will inevitably be developed to control the COVID-19 pandemic in the future.
New guidance came out yesterday
https://www.fda.gov/media/146173/download
Development of Monoclonal Antibody
Products Targeting SARS-CoV-2 for
Emergency Use Authorization
Guidance for Industry
INTRODUCTION
FDA is issuing this guidance to provide recommendations to sponsors on the development of
monoclonal antibody (mAb) products targeting SARS-CoV-2 intended for the prevention or
treatment of COVID-19, including recommendations on addressing the impact of emerging
variants.
Covidity anyone ? that European company ? . Listen again 46 mins to what Larry said
https://sanantonioreport.org/san-antonio-growing-biosciences-industry-bexar-county-jobs/
Teas Biomed maybe just sitting on the Unmet need the FDA are looking for
Https://images.app.goo.gl/L5w9KWKeDUAH5EP59
He also seems to have also received a promotion?
Very positive that the company is well funded , (without any deals that may land )
to go deeper and longer into the trials , to ensure the best price for the IP .No danger of taking a cheap deal , why Moderna may be in trouble !
see below
The FDA in September found quality control problems at Moderna’s main manufacturing plant, including issues with equipment that the company used to produce its COVID-19 vaccine, according to an exclusive report by Reuters published Friday.
The lapses were flagged during an FDA inspection from September 11 to 21 at Moderna’s site in Norwood, Massachusetts, according to documents that Reuters obtained via a Freedom of Information Act request.
https://www.biospace.com/article/fda-finds-quality-control-problems-at-moderna-s-vaccine-facility-reuters/
The Panel at the Recent Texas Biomed . Texas research , when asked 46 mins as pointed out by JohnnyB
Sincerely hop that Stephen and Martin Diggle are talking to the Singapore government about the sustainable Covidity vaccine :
Vulpes Investment Management Pte. Ltd.
Web pagehttps://www.vulpesinvest.com
Vulpes Investment Management Pte Ltd is a Singapore fund management company backed by a single family office, seeking alternative investment opportunities with a focus on long term value creation and alignment of interests with our Entrepreneurs and Investors. The Vulpes Life Science Fund is a co-investment fund that invests in companies that possess superior cutting-edge technology. The fund gives exposure to “best in class” technologies in the field of regenerative medicine. *
the recent panel where 46 mins in asked relevant question about Scancell ?
https://sanantonioreport.org/san-antonio-growing-biosciences-industry-bexar-county-jobs/
Therapeutic cancer vaccines: advancements, challenges, and prospects
Published 13 th December
Most interesting read . Burble value your opinion
https://www.nature.com/articles/s41392-023-01674-3#:~:text=Immunogenic%20neoantigens%20selection%20must%20be,scale%20implementation%20of%20this%20technology.
However, vaccine production time, vaccine design costs, and subsequent personalized neoantigen pool generation pose significant challenges for the large-scale implementation of this technology
DNA vaccine
DNA cancer vaccines are attractive because their efficient manufacturing process. DNA vaccines can simultaneously deliver multiple antigens in the same construct at the same time.
The full text is now available
There is under the radar company & CEO which is a non personalised DNA melanoma vaccine ?
Big news !
Profile in the Guardian of Lindy Durrant and Scancell
Interview with proactive investors Scancell CEO hails "exciting" high response rate to melanoma treatment
lindy durrant scancell
https://www.theguardian.com/business/2023/jun/20/designing-a-vaccine-that-covers-all-cancers-is-hard-biotech-pioneer-lindy-durrant
“Immuno-oncology is a rapidly growing market, estimated to exceed $300bn by 2030, according to Allied Market Research. The US firms Moderna – whose Covid jab has been a huge commercial success – and MSD (known as Merck in the US and Canada) are also working on a melanoma vaccine and hope to start late-stage trials before the end of 2023. Durrant says her rival’s vaccine is personalised, targeting the patient’s specific mutations, whereas Scancell’s one “is for everyone”. Germany’s BioNTech is also developing a melanoma vaccine, based on mRNA like its Covid jab.”
Recent article
https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/2023/231127-update-on-scope-27-11-23-final.pdf
Scancell Holdings plc
(“Scancell” or the “Company”)
Update on SCOPE trial
- 11 out of 13 patients have responded increasing the ORR to 85%
- One patient has achieved complete response following treatment
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and
infectious disease, announces today it has two further responders on the SCOPE study, bringing the number
of responders to 11 out of 13 patients. This is an objective response rate (ORR) of 85%. These responses have
been verified in nine patients with a second scan at 19 weeks. Significantly, one of the patients has achieved
a complete response following treatment. The two recent responders are scheduled to have their response
confirmed in a subsequent scan.
The SCOPE trial has now successfully transitioned into the second stage, which will recruit a further 27
patients (for a total of 43). The aim is to achieve at least 18 further responses (i.e., 27 responses in total)
which would statistically demonstrate that SCIB1, in combina
Yes BOJO 😂 or an Agatha Christie plot "vaccine vanishes "
After listening to the full podcast thanks Jonny B
These Texas research institutions and the pharma industry seem to be very linked in and lots . going on., not just 'non profit' , focused on making money and creating jobs , not just research , have a good listen please . Whilst I respect Bermuda opinion I found this panel to be commercially minded . also I knowing look between Randy Harig and Larry Schlesinger. when the questions was asked answer started " a company in Europe "
Excellent find , these institutions talk in terms of billions , our institutions talk in millions
please find profile of panel members
Heather Hanson president BIOMED SA
https://biomedsa.org/wp-content/uploads/2021/09/Hanson-Bio-Dec-2021.pdf
Randy Harig Texas research foundation .
https://capitalanalyticsassociates.com/spotlight-on-randy-harig-ceo-texas-research-technology-foundation/
Dr. Larry Schlesinger CEO serves as a Professor at Texas Biomed and is Principal Investigato .
https://www.txbiomed.org/about/leadership/dr-larry-schlesinger-presidentceo/
Violin I posted
RNS from scope trial on Melanoma Canada CEO Falyn Katz LinkedIn page ?
Maybe we need to send the other reporting journalists this news ?
As I said today Moderna have the trumpets out we are at the silent 🤫 disco
Clearly, they have a great Pr machine . One would maybe consider a good time to get something in the media about the “ trailblazing “ Scancell melanoma vaccine.
When will the new PR company be given the green light ?
https://globalnews.ca/news/10170629/moderna-melanoma-vaccine/
Extract:
It’s huge’: Vaccine for melanoma found to reduce recurrence, death by half
“It’s huge,” Melanoma Canada CEO Falyn Katz told Global News of the announcement. “This is a breakthrough
Seems a rush from Moderna before something better comes out for Melanoma ?
Listen to to the you tube link . Moderna has the Trumpets out . Merck are having a silent disco on the matter
https://amp.theguardian.com/business/2023/jun/20/designing-a-vaccine-that-covers-all-cancers-is-hard-biotech-pioneer-lindy-durrant
This is a very confident article and points to a way forward
Moderna vaccine whilst may have approved in 2025, it will be very expensive???? for insurance companies? Are therefore think that even if Scancell gets approval later than that it’s going to be more beneficial
Ah ok thanks Bermuda for the Clarity . Understandable it’s confusing 🫤
A reminder goes back to 2010 ?
Scancell licenses key ImmunoBody® patents from Merck Serono
Scancell Holdings Plc, the parent company of Scancell Limited (`Scancell'), the developer of therapeutic cancer vaccines based on its patented ImmunoBody® platform, is pleased to announce it has signed a licensing agreement with Merck KGaA, Darmstadt, Germany, acting for its division Merck Serono, for two key patents required for the further development and commercialisation of protein ImmunoBody® vaccines. Under the agreement, Scancell has non-exclusive worldwide rights to use the two patents to further develop and commercialise ImmunoBody® vaccines in all therapeutic areas in both humans and animals.
In addition, Scancell has granted Merck Serono an option to negotiate an exclusive license under Scancell's ImmunoBody® platform technology for up to five Merck Serono targets.
Scancell's ImmunoBody® is a breakthrough patent-protected platform technology that aims to overcome the current limitations of cancer vaccines by generating the high-avidity T-cells that kill cancer cells.
By re-engineering the vector, the Immunobody® platform technology can be adapted to provide the basis for treating any tumour type and may also be of utility in the development of vaccines against chronic infectious diseases including hepatitis and HIV.
Scancell's first cancer vaccine SCIB1 is being developed to treat melanoma, with clinical trials commencing in 2010.
David Evans, chairman of Scancell, commented:
"We are delighted to have forged this association with Merck Serono. The agreement will add further strength to Scancell's IP position, as it continues to progress its development of therapeutic vaccines based on the Immunobody® platform."
This is worth a watch wait until after the adverts
seems company split on opinion Merck v Moderna
either way suspect both these companies are watching Scancell
https://www.youtube.com/watch?v=9PfJVkO3s5I
Https://academic.oup.com/discovimmunology/article/2/1/kyac011/6874811
Who said at the AGM Lindy Durrant mentioned , after she had delivered her speech at the vaccine congress some one said from Moderna either " It works were, were in trouble '? or " it works we are in trouble " ?
Lots of buys this morning at 11p , ja question for those who attended the AGM. There was going to be an evaluation of a cell therapy company within six months ( presume now completed )did anybody ask the question about this company ?
results from Modi 1 and melanoma vaccine, should be soon and to see when Mandeep's first deal will come through it's getting rather exciting